Advanced Plant Pharmaceuticals Inc. - APPI - Finalizes Annual Report

    NEW YORK, April 17 /PRNewswire/ -- Advanced Plant Pharmaceuticals, Inc.
 (OTC Bulletin Board:   APPI) a company that utilizes whole plants to develop all
 natural dietary supplements, announced today that the Company is currently
 completing the year end audit and anticipates to have the Form 10-KSB filed
 within the next five days.  All that the Company is waiting for is the final
 submission of the audit by the auditing firm.
     APPI is a company that develops innovative plant formulations and
 technology for clinical application.  APPI has developed ACA TM, which has
 potential as an immunomodulator in the treatment of patients infected with the
 HIV virus as well as increasing energy levels in people that suffer from CFS
 (chronic fatigue syndrome).  APPI has also developed Lo-Chol TM, a patented
 cholesterol reducing dietary supplement proven in clinical studies to reduce
 total cholesterol up to 58%, reduce triglycerides up to 45%, increase HDL
 (good cholesterol) up to 60%, and improve the ratio of HDL to LDL up to 46%.
 APPI's newest product Sinusol TM is a generalized base solution for the
 development of an extensive line of specialty products related to allergy and
 sinus conditions.  The ingredients include a mixture of gently pH-balanced
 essential mineral oils that combat the various symptoms related to allergies
 and sinus disorders including congestions, irritated nasal mucosa, and
 bacterial and fungal infections.  APPI's "Whole Plant" Pharmaceutical Grade
 Process is a trade secret.  Utilization of the APPI process converts single or
 multiple whole plants into all-natural standardized dietary supplements.
 For more information on APPI, please visit the Company's Web site at
 http://www.appi.cc
 
     FORWARD LOOKING STATEMENTS:
     This release contains forward-looking statements within the meaning and
 pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act
 of 1995 and involve risks and uncertainties that may individually or mutually
 impact the matters herein described, including but not limited to product
 development and acceptance, manufacturing, competition, regulatory and/or
 other factors, which are outside the control of the Company.
 
 

SOURCE  Advanced Plant Pharmaceuticals, Inc.

    NEW YORK, April 17 /PRNewswire/ -- Advanced Plant Pharmaceuticals, Inc.
 (OTC Bulletin Board:   APPI) a company that utilizes whole plants to develop all
 natural dietary supplements, announced today that the Company is currently
 completing the year end audit and anticipates to have the Form 10-KSB filed
 within the next five days.  All that the Company is waiting for is the final
 submission of the audit by the auditing firm.
     APPI is a company that develops innovative plant formulations and
 technology for clinical application.  APPI has developed ACA TM, which has
 potential as an immunomodulator in the treatment of patients infected with the
 HIV virus as well as increasing energy levels in people that suffer from CFS
 (chronic fatigue syndrome).  APPI has also developed Lo-Chol TM, a patented
 cholesterol reducing dietary supplement proven in clinical studies to reduce
 total cholesterol up to 58%, reduce triglycerides up to 45%, increase HDL
 (good cholesterol) up to 60%, and improve the ratio of HDL to LDL up to 46%.
 APPI's newest product Sinusol TM is a generalized base solution for the
 development of an extensive line of specialty products related to allergy and
 sinus conditions.  The ingredients include a mixture of gently pH-balanced
 essential mineral oils that combat the various symptoms related to allergies
 and sinus disorders including congestions, irritated nasal mucosa, and
 bacterial and fungal infections.  APPI's "Whole Plant" Pharmaceutical Grade
 Process is a trade secret.  Utilization of the APPI process converts single or
 multiple whole plants into all-natural standardized dietary supplements.
 For more information on APPI, please visit the Company's Web site at
 http://www.appi.cc
 
     FORWARD LOOKING STATEMENTS:
     This release contains forward-looking statements within the meaning and
 pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act
 of 1995 and involve risks and uncertainties that may individually or mutually
 impact the matters herein described, including but not limited to product
 development and acceptance, manufacturing, competition, regulatory and/or
 other factors, which are outside the control of the Company.
 
 SOURCE  Advanced Plant Pharmaceuticals, Inc.